Liraglutide Injection Shortage
Last Updated: November 12, 2024
Status: Current
Products Affected - Description
-
- Victoza subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 2 count, NDC 00169-4060-12
- Victoza subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 3 count, NDC 00169-4060-13
Reason for the Shortage
-
- Novo Nordisk has Victoza on shortage due to manufacturing delays.
- Novo Nordisk has Saxenda available.
- Teva launched the authorized generic of liraglutide in late-June 2024.
Available Products
-
- Saxenda subcutaneous injection, Novo Nordisk, 6 mg/mL, 3 mL pen injector, 5 count, NDC 00169-2800-15
- Liraglutide subcutaneous injection, Teva, 6 mg/mL, 3 mL pen injector, 2 count, NDC 00480-3667-20
- Liraglutide subcutaneous injection, Teva, 6 mg/mL, 3 mL pen injector, 3 count, NDC 00480-3667-22
Estimated Resupply Dates
-
- Novo Nordisk has Victoza 6 mg/mL 3 mL pens in 2 and 3 count presentations on back order and the company estimates a release date in late-December 2024.
Updated
Updated November 12, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created July 20, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.